![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TBC1D7 |
Gene summary for TBC1D7 |
![]() |
Gene information | Species | Human | Gene symbol | TBC1D7 | Gene ID | 51256 |
Gene name | TBC1 domain family member 7 | |
Gene Alias | MGCPH | |
Cytomap | 6p24.1 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | A0A024QZX0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51256 | TBC1D7 | LZE2T | Human | Esophagus | ESCC | 3.01e-02 | 2.74e-01 | 0.082 |
51256 | TBC1D7 | LZE4T | Human | Esophagus | ESCC | 5.22e-10 | 2.36e-01 | 0.0811 |
51256 | TBC1D7 | LZE7T | Human | Esophagus | ESCC | 1.25e-28 | 1.75e+00 | 0.0667 |
51256 | TBC1D7 | LZE8T | Human | Esophagus | ESCC | 5.52e-05 | 2.83e-01 | 0.067 |
51256 | TBC1D7 | LZE20T | Human | Esophagus | ESCC | 6.42e-07 | 2.06e-01 | 0.0662 |
51256 | TBC1D7 | LZE22T | Human | Esophagus | ESCC | 7.52e-03 | 4.56e-01 | 0.068 |
51256 | TBC1D7 | LZE24T | Human | Esophagus | ESCC | 3.72e-12 | 2.89e-01 | 0.0596 |
51256 | TBC1D7 | LZE21T | Human | Esophagus | ESCC | 2.15e-02 | 3.10e-01 | 0.0655 |
51256 | TBC1D7 | LZE6T | Human | Esophagus | ESCC | 4.94e-07 | 3.34e-01 | 0.0845 |
51256 | TBC1D7 | P1T-E | Human | Esophagus | ESCC | 2.16e-12 | 5.06e-01 | 0.0875 |
51256 | TBC1D7 | P2T-E | Human | Esophagus | ESCC | 2.38e-32 | 6.35e-01 | 0.1177 |
51256 | TBC1D7 | P4T-E | Human | Esophagus | ESCC | 3.74e-35 | 7.82e-01 | 0.1323 |
51256 | TBC1D7 | P5T-E | Human | Esophagus | ESCC | 7.37e-12 | 2.94e-01 | 0.1327 |
51256 | TBC1D7 | P8T-E | Human | Esophagus | ESCC | 1.09e-15 | 3.44e-01 | 0.0889 |
51256 | TBC1D7 | P9T-E | Human | Esophagus | ESCC | 2.89e-16 | 3.39e-01 | 0.1131 |
51256 | TBC1D7 | P10T-E | Human | Esophagus | ESCC | 4.42e-39 | 6.17e-01 | 0.116 |
51256 | TBC1D7 | P11T-E | Human | Esophagus | ESCC | 1.66e-22 | 6.92e-01 | 0.1426 |
51256 | TBC1D7 | P12T-E | Human | Esophagus | ESCC | 1.22e-19 | 4.67e-01 | 0.1122 |
51256 | TBC1D7 | P15T-E | Human | Esophagus | ESCC | 5.25e-29 | 5.05e-01 | 0.1149 |
51256 | TBC1D7 | P16T-E | Human | Esophagus | ESCC | 1.66e-32 | 5.88e-01 | 0.1153 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:1902116 | Liver | HCC | negative regulation of organelle assembly | 28/7958 | 41/18723 | 7.54e-04 | 4.55e-03 | 28 |
GO:006049112 | Liver | HCC | regulation of cell projection assembly | 101/7958 | 188/18723 | 1.20e-03 | 6.69e-03 | 101 |
GO:012003212 | Liver | HCC | regulation of plasma membrane bounded cell projection assembly | 100/7958 | 186/18723 | 1.23e-03 | 6.81e-03 | 100 |
GO:190332020 | Oral cavity | OSCC | regulation of protein modification by small protein conjugation or removal | 165/7305 | 242/18723 | 2.52e-20 | 3.99e-18 | 165 |
GO:003139620 | Oral cavity | OSCC | regulation of protein ubiquitination | 143/7305 | 210/18723 | 1.01e-17 | 9.80e-16 | 143 |
GO:001063918 | Oral cavity | OSCC | negative regulation of organelle organization | 190/7305 | 348/18723 | 2.12e-09 | 4.97e-08 | 190 |
GO:19033227 | Oral cavity | OSCC | positive regulation of protein modification by small protein conjugation or removal | 88/7305 | 138/18723 | 3.24e-09 | 7.39e-08 | 88 |
GO:19021155 | Oral cavity | OSCC | regulation of organelle assembly | 109/7305 | 186/18723 | 4.54e-08 | 8.45e-07 | 109 |
GO:00313986 | Oral cavity | OSCC | positive regulation of protein ubiquitination | 75/7305 | 119/18723 | 9.46e-08 | 1.65e-06 | 75 |
GO:006049110 | Oral cavity | OSCC | regulation of cell projection assembly | 100/7305 | 188/18723 | 5.27e-05 | 4.38e-04 | 100 |
GO:012003216 | Oral cavity | OSCC | regulation of plasma membrane bounded cell projection assembly | 98/7305 | 186/18723 | 1.00e-04 | 7.54e-04 | 98 |
GO:004308710 | Oral cavity | OSCC | regulation of GTPase activity | 165/7305 | 348/18723 | 7.94e-04 | 4.27e-03 | 165 |
GO:00319293 | Oral cavity | OSCC | TOR signaling | 67/7305 | 126/18723 | 8.52e-04 | 4.50e-03 | 67 |
GO:19021161 | Oral cavity | OSCC | negative regulation of organelle assembly | 26/7305 | 41/18723 | 1.34e-03 | 6.62e-03 | 26 |
GO:00313458 | Oral cavity | OSCC | negative regulation of cell projection organization | 89/7305 | 186/18723 | 8.51e-03 | 3.09e-02 | 89 |
GO:1903320110 | Oral cavity | LP | regulation of protein modification by small protein conjugation or removal | 111/4623 | 242/18723 | 4.81e-13 | 4.30e-11 | 111 |
GO:0031396110 | Oral cavity | LP | regulation of protein ubiquitination | 95/4623 | 210/18723 | 5.88e-11 | 3.61e-09 | 95 |
GO:001063919 | Oral cavity | LP | negative regulation of organelle organization | 127/4623 | 348/18723 | 5.07e-07 | 1.40e-05 | 127 |
GO:190332215 | Oral cavity | LP | positive regulation of protein modification by small protein conjugation or removal | 57/4623 | 138/18723 | 1.24e-05 | 2.23e-04 | 57 |
GO:190211513 | Oral cavity | LP | regulation of organelle assembly | 71/4623 | 186/18723 | 2.94e-05 | 4.58e-04 | 71 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa041505 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
hsa0415013 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
hsa041502 | Liver | HCC | mTOR signaling pathway | 95/4020 | 156/8465 | 4.70e-04 | 1.99e-03 | 1.11e-03 | 95 |
hsa0415011 | Liver | HCC | mTOR signaling pathway | 95/4020 | 156/8465 | 4.70e-04 | 1.99e-03 | 1.11e-03 | 95 |
hsa041504 | Oral cavity | OSCC | mTOR signaling pathway | 90/3704 | 156/8465 | 2.87e-04 | 9.15e-04 | 4.66e-04 | 90 |
hsa0415012 | Oral cavity | OSCC | mTOR signaling pathway | 90/3704 | 156/8465 | 2.87e-04 | 9.15e-04 | 4.66e-04 | 90 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TBC1D7 | SNV | Missense_Mutation | c.592N>A | p.Ala198Thr | p.A198T | Q9P0N9 | protein_coding | deleterious(0.01) | benign(0.003) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
TBC1D7 | insertion | Nonsense_Mutation | novel | c.394_395insGGACTTGCAAATAGTATTTGCATATAACCTACACATCTCTTCCT | p.Glu132GlyfsTer5 | p.E132Gfs*5 | Q9P0N9 | protein_coding | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | SD | |||
TBC1D7 | deletion | Frame_Shift_Del | novel | c.633delN | p.Phe211LeufsTer18 | p.F211Lfs*18 | Q9P0N9 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
TBC1D7 | SNV | Missense_Mutation | novel | c.814N>A | p.Asp272Asn | p.D272N | Q9P0N9 | protein_coding | deleterious(0) | probably_damaging(0.911) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TBC1D7 | SNV | Missense_Mutation | c.362N>A | p.Arg121Gln | p.R121Q | Q9P0N9 | protein_coding | tolerated(0.29) | benign(0.005) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
TBC1D7 | SNV | Missense_Mutation | rs767151296 | c.499C>T | p.Arg167Trp | p.R167W | Q9P0N9 | protein_coding | tolerated(0.06) | possibly_damaging(0.609) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
TBC1D7 | SNV | Missense_Mutation | rs766235427 | c.721N>A | p.Glu241Lys | p.E241K | Q9P0N9 | protein_coding | tolerated(0.56) | probably_damaging(0.945) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TBC1D7 | SNV | Missense_Mutation | rs766235427 | c.721G>A | p.Glu241Lys | p.E241K | Q9P0N9 | protein_coding | tolerated(0.56) | probably_damaging(0.945) | TCGA-G5-6233-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
TBC1D7 | SNV | Missense_Mutation | novel | c.511N>T | p.Pro171Ser | p.P171S | Q9P0N9 | protein_coding | deleterious(0.03) | benign(0.175) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TBC1D7 | SNV | Missense_Mutation | novel | c.337N>A | p.Gln113Lys | p.Q113K | Q9P0N9 | protein_coding | tolerated(1) | benign(0.283) | TCGA-A5-A0GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |